Evaluating Efficacy of Aflibercept in Refractory Exudative Age-Related Macular Degeneration With OCT Segmentation Volumetric Analysis

Catherine S Choi; Li Zhang; Michael D Abràmoff; Milan Sonka; Amde Selassie Shifera; Christine N Kay

doi:10.3928/23258160-20160229-07

$Evaluating Efficacy of Aflibercept in Refractory Exudative Age-Related Macular Degeneration With OCT Segmentation Volumetric Analysis$

Journal article

Open access

Peer reviewed

Evaluating Efficacy of Aflibercept in Refractory Exudative Age-Related Macular Degeneration With OCT Segmentation Volumetric Analysis

Catherine S Choi, Li Zhang, Michael D Abràmoff, Milan Sonka, Amde Selassie Shifera and Christine N Kay

Ophthalmic surgery, lasers & imaging retina, Vol.47(3), pp.245-251

03/2016

DOI: 10.3928/23258160-20160229-07

PMCID: PMC5750045

PMID: 26985798

View Online

Abstract

To use automated segmentation software to analyze spectral-domain optical coherence tomography (SD-OCT) scans and evaluate the effectiveness of aflibercept (Eylea; Regeneron, Tarrytown, NY) in the treatment of patients with exudative age-related macular degeneration (AMD) refractory to other treatments. Retrospective chart review of 16 patients refractory to bevacizumab (Avastin; Genentech, South San Francisco, CA)/ranibizumab (Lucentis; Genentech, San Francisco, CA) treatment was conducted. Visual acuity, central foveal thickness (CFT), maximum fluid height, pigment epithelial detachment (PED) volume, sub-retinal fluid (SRF) volume, fluid-free time interval, and adverse effects were evaluated. Automated segmentation analysis was used to quantify improvement. With aflibercept treatment, there was a statistically significant improvement in visual acuity by 1 line (P = .020), in CFT by 74.02 µm (P = .001), and in maximum fluid height by 31.9 µm (P= .011). Total PED and SRF volume also decreased significantly by 1.50 µm(3) × 10(8) µm(3) (P = .013). Anatomic improvement was confirmed by automated segmentation analysis. This study demonstrates utility of automated segmentation software in quantifying anatomic improvement with aflibercept treatment in exudative AMD refractory to other anti-vascular endothelial growth factor treatments.

Receptors, Vascular Endothelial Growth Factor - therapeutic use

Tomography, Optical Coherence

Humans

Middle Aged

Recombinant Fusion Proteins - therapeutic use

Male

Treatment Outcome

Vascular Endothelial Growth Factor A - antagonists & inhibitors

Visual Acuity - drug effects

Wet Macular Degeneration - diagnostic imaging

Wet Macular Degeneration - drug therapy

Subretinal Fluid

Aged, 80 and over

Angiogenesis Inhibitors - therapeutic use

Female

Aged

Retrospective Studies

Exudates and Transudates

Details

Title: Subtitle: Evaluating Efficacy of Aflibercept in Refractory Exudative Age-Related Macular Degeneration With OCT Segmentation Volumetric Analysis
Creators: Catherine S Choi
Li Zhang
Michael D Abràmoff
Milan Sonka
Amde Selassie Shifera
Christine N Kay
Resource Type: Journal article
Publication Details: Ophthalmic surgery, lasers & imaging retina, Vol.47(3), pp.245-251
DOI: 10.3928/23258160-20160229-07
PMID: 26985798
PMCID: PMC5750045
NLM abbreviation: Ophthalmic Surg Lasers Imaging Retina
ISSN: 2325-8179
eISSN: 2325-8179
Publisher: SLACK, Inc.; United States
Grant note: R01-EB004640 / NIBIB NIH HHS R01-EY018853 / NEI NIH HHS R01 EB004640 / NIBIB NIH HHS R01 EY019112 / NEI NIH HHS EY018853 / NEI NIH HHS R01 EY018853 / NEI NIH HHS R01-EY017066 / NEI NIH HHS
Language: English
Date published: 03/2016
Academic Unit: Roy J. Carver Department of Biomedical Engineering; Electrical and Computer Engineering; Radiation Oncology; Injury Prevention Research Center; Ophthalmology and Visual Sciences
Record Identifier: 9983806381002771

Metrics

15 Record Views

4 Times Cited - Web of Science

See more details